From: Donald Rubin

EFTA01786714 Dataset 10 5 pages Download original PDF Download as text
From: Donald Rubin Sent: Wednesday, December 7, 2016 5:47 PM To: jeffrey E. Subject: Re: Placebo effects, EB, etc. Think so. Where will you be? On =ec 7, 2016, at 12:25 PM, jeffrey E. <[email protected]> wrote: ar you around on the weekend in cambridge.? =nbsp; On Wed, Dec 7, 2016 at 1:10 PM, Donald Rubin mails wrote: OK. ='ll get back to you after I make contact with Adriaan again, =nd my plans settle a bit. On Dec 7, 2016, at 10:38 AM, =effrey E. <[email protected] <mailto:[email protected]> wrote: three way skype for 3. and =es 1 face to face On Wed, Dec 7, 2016 at 11:37 AM, =onald Rubin Different ways to follow up. wrote: 1. The next time =hat we're in the same town, we could talk about the statistical =deal underlying ways to disentangle placebo effects from biological =ffects of drugs and why that's important for FDA approvals and =or prescripts in the docs office — different answers, I =hink. that wonderfully written. lives in =msterdam. arranged either here or there. 2. = can send some recent things on the topic of placebo response, which =re still not 3. If interested in exploring =nvesting in EB, I can put you in touch with Adriaan, who Are =ny of these appealing? I prefer 1 to 2. I think a face to =ace version of 3 could be Let me =now. EFTA_R1_00109659 EFTA01786714 On Dec 7, 2016, at 9:35 AM, jeffrey E. <[email protected]> wrote: I'm always =nterested in unique idea On Wed, Dec 7, 2016 at 10:12 AM =onald Rubin wrote: Hello =effrey, l'= glad that Martin has put us in touch for a couple of reasons. =irst, I think we have some mutual interests concerning the =omplications of doing experiments with humans, rather than plants or =nimals or tires. One complication is noncompliance with the =ssigned treatment, which we briefly discussed at the dinner, but the =ore interesting one is the placebo effect, which can be gigantic, for =xample in "viagra" type studies, which we didn't =et around to discussing except indirectly in the context of the =motional Brain (EB) female viagra issue. More =enerally, this is related to FDA standards for approving drugs. A =light aside: in January I'm one of three people getting =onorary degrees from the Medical Faculty of the University of Uppsala =n Sweden, where one of the others is Robert Califf, the current =ommissioner of the FDA (the other is Marcia McNutt, the current =resident of the National Academy of Sciences), so I should get the =hance to bend his ear at various meals (a former commissioner — =nder Bush II — was a partial PhD student of mine when he was =etting his MD at Harvard and his PhD in Econ at MIT, and remains a good =riend: Mark McClellen, who is interested in this stuff and remains =uite influential in DC, I think). But the =eason for rambling about the FDA and placebo effects is the =ollowing. This morning I just had an exchange of emails with the =EO of EB, whom I've known and worked with for about three =ears, Adriaan Tuiten. He wrote that FDA has agreed with EB'= proposal for more trials, and the EB board of directors just approved =he issuance of about 12 million Euros in stock to pay for these =rials. Adriaan thinks that they may have enough connections now, =ut would you be interested in participating? I already have some =tock, which I earned though consulting. I think EB is =nteresting but still needs more wisdom when it comes to their =tatistics (I've been to FDA with them two or three times, and I =hink they still need help with some of their ideas e.g., using =NPs). If interested in tossing some money their way, let me =now. In any =ase, I very much enjoyed our last conversations, and I look forward to =eeing you again, either in Cambridge or in NYC, which I'll =robably get to in the next couple of weeks. Best =ishes, Don Donald B. Rubin John L =oeb Professor of Statistics Department=of Statistics, Harvard University 1 Oxford =treet 2 EFTA_R1_00109660 EFTA01786715 On Dec =, 2016, at 9:41 AM, jeffrey E. <[email protected]> wrote: great On Fri, Dec 2, =016 at 9:40 AM, Donald Rubin wrote: Great, thanks Martin. Sometime when I =et to NYC, which I often do to visit Columbia connections, I'd =ike to be in touch, and give Jeffery more lectures in statistics —=1 think he has some potential! Also, Martin, should we try to touch base on =onday? The rest of the week is pretty much shot for me with =isitors. Best, Don > On Dec 2, 2016, at 9:32 AM, Nowak, Martin = <mailto wrote: > Don , Jeffrey 3 EFTA_R1_00109661 EFTA01786716 > I would like to put you in direct email =ontact. > also cc >m &nbs=; please note The =nformation contained in this communication is confidenti=l, may be attorney-client privileged, may constitute=inside information, and is intended only for the use =f the addressee. It is the property of JEE Unauthoriz=d use, disclosure or copying of this communicat=on or any part thereof is strictly prohibited and may =e unlawful. If you have received this communicat=on in error, please notify us immediately by return =-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy =his communication and all copies thereof, including =11 attachments. copyright -all rights reserved 4 EFTA_R1_00109662 EFTA01786717 please note The information contained in this =ommunication is confidential, may be attorney-client =rivileged, may constitute inside information, and is =ntended only for the use of the addressee. It is the =roperty of JEE Unauthorized use, disclosure =r copying of this communication or any part thereof is =trictly prohibited and may be unlawful. If you have =eceived this communication in error, please notify us =mmediately by return e-mail or by e-mail to [email protected], and destroy this =ommunication and all copies thereof, including all =ttachments. copyright -all rights reserved please note The information contained in this =ommunication is confidential, may be attorney-client =rivileged, may constitute inside information, and is =ntended only for the use of the addressee. It is the =roperty of JEE Unauthorized use, disclosure =r copying of this communication or any part thereof is =trictly prohibited and may be unlawful. If you have =eceived this communication in error, please notify us =mmediately by return e-mail or by e-mail to [email protected], and destroy this =ommunication and all copies thereof, including all =ttachments. copyright -all rights reserved 5 EFTA_R1_00109663 EFTA01786718

📷 Images in this document (5 detected)

AI-generated factual descriptions of embedded images (llava:13b). These are searchable across the corpus.

[Image 1] The image shows a document that appears to be a letter or an email. The document is addressed to an individual named "David" and is signed by "Dan." The text of the document discusses a scientific study or paper, mentioning the "Human Genome Project" and "Nature Genetics." There are also references to "HIV," "Hepatitis C," and "Hepatitis B." The document includes a paragraph that seems to be a dis [Image 2] The image shows a document that appears to be a letter or an email. The document contains text, which seems to be a conversation or correspondence between two individuals. The text includes phrases such as "I'm not sure what you're asking," "I'm not sure what you're trying to say," and "I'm not sure what you're trying to do." There are also mentions of "I'm not sure what you're trying to say," "I' [Image 3] The image shows a document with text, which appears to be a letter or a note. The text is written in English and includes a salutation, a body with several paragraphs, and a closing. The document is printed on a white background with black text. There are no visible names, dates, places, or logos that can be discerned from this image. The text is too small to read in detail, but it seems to be a f [Image 4] The image appears to be a photograph of a printed document, possibly a letter or a form. The text is too small and blurry to read clearly, but it seems to be a standard letter format with a header, body, and footer. The document contains text, which is the main content visible. There are no distinctive logos, names, or other identifiable features that would provide additional context about the doc [Image 5] The image appears to be a photograph of a printed document, possibly a letter or an email, with some text visible. The document contains a date at the top, which seems to be December 15, 2010. There is a sender's name and email address at the top, followed by a recipient's name and email address at the bottom. The visible text includes a subject line that reads "Re: [Subject]." Below the subject l